key: cord-0744780-gaaecxmp
authors: Duran, Nizami; Polat, M. Fatih; Aktas, Derya Anil; Alagoz, M. Abdullah; Ay, Emrah; Cimen, Funda; Tek, Erhan; Anil, Baris; Burmaoglu, Serdar; Algul, Oztekin
title: New chalcone derivatives as effective against SARS‐CoV‐2 agent
date: 2021-09-25
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14846
sha: 73693f091b00825713c2e22da86c69fccdbf741e
doc_id: 744780
cord_uid: gaaecxmp

AIMS: Flavonoids and related compounds, such as quercetin‐based antiviral drug Gene‐Eden‐VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS‐CoV proteases. In this study, we aimed to compare the anti‐SARS CoV‐2 activities of both newly synthesized chalcone derivatives and these two drugs. METHODS: Determination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS‐CoV‐2 by calculating the RT‐PCR cycling threshold (C(t) ) values. RESULTS: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS‐CoV‐2 at the concentration of 1.60 µg/mL. Structure‐based virtual screening was carried out against the most important druggable SARS‐CoV‐2 targets, viral RNA‐dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti‐coronavirus disease‐2019 drug candidates. CONCLUSIONS: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from −4.370 to −2.748 kcal/mol along with their toxicological, ADME, and drug‐like properties.

treatment, coronavirus-specific treatment, antiviral treatment, and other methods. 1, 2 General treatment includes nutritional supplements, immune boosters, and some alternative medications in folk medicine. 3 Various treatment strategies based on the use of available drugs have been tried against SARS-CoV-2 globally, but no effective treatment protocol has been found. There are many drugs, such as chloroquine/hydroxychloroquine, favipiravir, ribavirin, remdesivir, or combinations of these drugs, which are found to be effective against SARS-CoV-2. 4 Although some studies initially reported that one or more of these drugs were effective against SARS-CoV-2 in some countries, later some scientific studies reported that these drugs did not have the expected level of effectiveness against SARS-CoV-2. 4, 5 Previous treatments targeting SARS-CoV and Middle East respiratory syndrome coronavirus may accelerate the development of the COVID-19 treatment because of their structural and genomic similarities. Antiviral effective therapies act by arresting viral replication stages and the inactivation or inhibition of the enzymes or steps involved in these stages. One of the best characterized and conserved drug targets of coronaviruses is integrase, the main protease proteins. Inhibiting the activity of this enzyme would block viral replication, for which protease inhibitors are used. One of the most important targets that can inhibit viral replication against SARS-CoV-2 is the inactivation of the RNAdependent RNA polymerase (RdRp) enzyme. Inactivation of this enzyme prevents virus replication. Today, some of the available protease and RNA polymerase enzyme inhibitor drugs are being redesigned to treat SARS-CoV-2. [6] [7] [8] [9] In cases where vaccines against SARS-CoV-2 may be insufficient, humanity's most important weapon would be an effective antiviral drug. For this reason, it is crucial to produce an effective antiviral drug against this highly contagious and deadly virus. Small modifications to the inhibitory ligand can significantly induce conformational changes in the molecules by changing the protein's binding modes and interactions to the active site and thus their activity.

In this context, some compounds that inhibit viral RNA polymerases in the literature were examined to find a scaffold, which would be active against COVID-19. The scaffold was determined to show the best activity against COVID-19. Various modifications were made to chalcone structure to design a newer, more active compound and reach the target molecules.

A target molecule that could be effective against COVID-19 was designed.

Chalcone derivatives are the building blocks of pharmaceutical raw materials that have long been used to treat various diseases, and medicinal plants are structural analogs of the flavonoids they carry. Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of SARS-CoV-2. 10 Chalcones also exhibit inhibitory activity against tobacco mosaic virus, 11 HIV, 12 herpes simplex virus, 13 and dengue virus. 14 It also exhibits antioxidant, 15 antimicrobial, 16 antimycobacterial, 17 and antileishmanial 18 properties. Antiviral properties of chalcones have been determined in studies on plant viruses and human rhinoviruses. 19 Studies on hydroxy or methoxy-containing chalcones have confirmed that these chalcone derivatives show antiviral properties depending on the positions of the OH/OMe groups and the nature of the chalcone skeleton. 20 Additionally, the alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. 21 The current study aimed to determine the inhibitory activities of new eight chalcone derivatives against SARS-CoV-2 by calculating the SARS-CoV-2 RT-PCR Cycling threshold (C t ) values. Moreover, the toxicological, ADME, and drug-like properties of the compounds were also determined by in silico method. The solvent was evaporated in vacuum. HCl solution of 2 mol/L (5 mL) was added, and the crude material was extracted with ethyl acetate (EtOAc) (25 mL × 3). The combined extracts were dried over Na 2 SO 4 .

The solvent was removed in vacuum and the remaining residue was purified via column chromatography over silicagel using gradient elution with EtOAc and hexanes to yield compound 6-9.

2.2.1 | (E)-1-(2,5-Difluorophenyl)-3-(2,4,6trimethoxyphenyl)prop-2-en-1-one (6) The above procedure was followed with 2,5-difluoroacetophenone (2) 2.2.2 | (E)-1-(3,5-Difluorophenyl)-3-(2,4,6trimethoxyphenyl)prop-2-en-1-one (7) The above procedure was followed with 3,5-difluoroacetophenone (3) to yield 7 as a yellow solid (65% yield). 2.2.4 | (E)-1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2,4,6-trimethoxyphenyl)prop-2-en-1-one (9) The above procedure was followed with 3,5-bistrifluoromethylacetop henone (5) to yield 9 as a yellow solid (73% yield 

To a solution of ammonium cerium (IV) nitrate (1 eq.) and LiBr (1 eq.) in CH 3 CN (2.5 mL/1 mmol of substrate) was added 2-hydroxy-4,6-dimet hoxyacetophenone (10) (1 eq.). The mixture was stirred for 6 hours at room temperature. After 6 hours, the reaction was monitored by TLC 

The above procedure was followed with 3,5-difluorobenzaldehyde 

The above procedure was followed with 2,4,5-trifluorobenzaldehyde (12) to yield 16 as a yellow solid (60% yield). 

The SARS-CoV-2 Hatay strain (SARS-CoV-2, Hatay, 2020), isolated by Professor Dr Nizami Duran, was used in the study. The SARS-CoV-2 strain was propagated in the Vero E6 cell line (African green monkey kidney cells), obtained from the American Type Culture Collection (ATCC C1008). After 7 days of incubation at 37°C in an atmosphere of 5% CO 2 , the supernatant was harvested. All necessary permissions have been obtained for the present study.

Vero E6 cell line was used for viral isolation. Cell cultures were maintained with 10% fetal calf serum in RPMI-1640 (Sigma-Aldrich, USA) medium containing 10 mM HEPES, 4 IM glutamine, and 100 IU/mL penicillin/streptomycin. Incubation of cells was carried out at 37°C in an incubator with 95% air and 5% CO 2 . Cell density was adjusted to 1 × 10 5 cells/mL. Experiments were performed by adding cell maintenance medium to 10% of the culture dish in culture dishes. Incubation of cell cultures continued for 96 hours. Cells were removed from the culture vessels with 0.25% trypsinization solution and collected in 50 mL centrifuge tubes by centrifugation at 300 g for 10 minutes at the end of incubation. Cell number and viability were determined by hemocytometer with 1% trypan blue dye prepared in 0.9% NaCl.

Viral growth was confirmed both by determining the presence of cytopathological effect (CPE) and by the real-time PCR method. The formation of CPE was detected on the 4th day in the Vero cell line.

DMSO was used to dissolve the chemical compounds at a concentration nontoxic to Vero cells. Proliferation experiments in cell culture were performed on 24-well flat-bottom microplates. The wells were prepared with RPMI-1640 medium containing 10% fetal calf serum at a density of 1 × 10 5 cells/mL.

Stock viral strains (maintained at −80°C) were rapidly dissolved in 37°C water (in a bain-marie) and were re-activated in cell lines (Vero E6 cell line). The cells were then exploded by "freezing and thawing." Cells were collected from the culture dish and centrifuged at 1200 g for 20 minutes, and the supernatant virus was collected as a stock solution. Like in our previous study in which TCID 50 of the virus was calculated; in the present study, three different titers of SARS-CoV-2 (1, 10, and 100 TCID 50 ) were chosen to be studied. 23 

This method is based on the principle of the cleavage of the 3-(4

tetrazolium ring in active mitochondria. In this method, cultured live cells can be detected colorimetrically and quantitatively. The MTT method, first described by Mosmann and later developed, is a practical method used to determine cell viability. 24 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is a substance that is actively absorbed into cells and is reduced to col- In the MTT assay, the decrease in cell viability was associated with increased viral replication, whereas high cell viability was considered as an indicator of antiviral activity. For this purpose, seawater at different concentrations was added to the SARS-CoV-2 inoculated cell lines and was incubated for 96 hours in an incubator with 5% carbon dioxide at 37°C. MTT, 10 µL, was added to each well, and the plates were incubated for 4 hours under the same conditions. Absorbance measurements were made at 570 nm on a spectrophotometer.

Severe acute respiratory syndrome coronavirus 2 replication in cell culture was verified by the real-time PCR method. Compared with the control group using the real-time PCR method, the presence or increase of viral replication was described as an increased number of viral copies. Viral RNA extraction was performed using a commercial kit under the commercial kit procedure. In the studies, the SYBR-Green RT-qPCR method was performed in accordance with the QuantiTect SYBR-Green PCR kit (Qiagen, Germany) test procedure.

The PCR cycle starts with an initial denaturation at 95°C for 15 minutes, followed by three steps of 45 cycles of 94°C for 15 seconds, annealing at 60°C for 30 seconds and elongation at 72°C for 30 seconds, and a final extension temperature of 72°C for 10 minutes. The Human β-actin gene (QuantiTect Primer Assays; Qiagen) was used as the reference gene. All reactions were tested in triplicate at different intervals. 25 

In isolation, "C t " values provide a relative measure of the viral quantity in the sample. Different known quantities of standards were included in the same study and tested in parallel with viral cultures.

Thus, the "C t " value could potentially provide some measure of viral copies. 26, 27 An 8-to 10-fold dilutions series was prepared from the culture filtrate for SARS-CoV-2. Five replicates of each dilution were tested in parallel. All replicates were detected at dilutions of 10 −1 to 10 −5 . 28

Molecular modeling studies were conducted using Maestro 11.8 software. The poses obtained from docking were examined, and appropriate docking scores were determined, as given in Table 1 . 32

All data were evaluated by the statistical tests (ie χ 2 , paired t-test, and independent sample t-test) using Statistical Package for Social Sciences (SPSS for Windows. 18.0, Chicago, IL, USA) software. Pvalues < .05 were considered to be statistically significant.

The synthesis of the target molecules (6-9) was accomplished in one step using the Claisen-Schmidt condensation reaction, as illustrated in Figure 1 . The corresponding chalcones were obtained in high purity and good yields by treating 2,4,6-trimethoxy benzaldehyde The synthesis of the second group of compounds (13) (14) (15) (16) was accomplished in two steps using bromination of compound The "C t " values give a relative measure of the viral copy number in the sample compared with the curves using the standards. Different known quantities of standards were included in the same study and tested in parallel with viral cultures. Therefore, the "C t " value was evaluated as the potential viral (SARS-CoV-2) copy number. In this study, the inhibitory activities of new chalcone derivatives against SARS-CoV-2 were determined by calculating the SARS-CoV-2 RT-PCR "C t " values. 26, 27 It has been reported that low C t values (high viral load) can be considered an indicator of severe disease and high contagiousness.

In contrast, high C t values (low viral load) indicate a decrease in both the risk of infection and contagiousness. 34 As shown in Figure 4 , the efficacy of compounds 6-9, 14, and Table 2 .

The replication mechanism of SARS-CoV-2 is mainly governed by RdRp, the nsps 12, 8, and 7 complexes. 36 This 6M71 PDBencoded RdRp protein is mainly extracted from SARS-CoV2. 37 It has been reported that Ser759, Asp760, Asp761, Asp618, residues located in the catalytic region of the protein, are required for replication. 9, 37 The docking scores of the compounds varied between −4,340 and −3,266 kcal/mol. As a result of docking studies, compound 6 made a hydrogen bond with Ser814; a charged (negative) interaction with Asp760, Asp761, Asp618, and its binding affinity was determined at −4,370 kcal/mol, as shown in Figure 6 .

It has been reported that quercetin is a potential inhibitor of Determined by pre-admet (https://pread met.bmdrc.kr).

Chalcone derivatives were also analyzed in silico for their pharmacokinetic properties and were validated as having drug-like nature.

This library was considered for tackling the modern-day issue of SARS-CoV-2 and further tested against homology modeled M pro , RdRp, and S proteins. Considering the potential efficacy of these newly synthesized compounds against SARS-CoV-2, we believe that these molecules may be the potentially effective drug candidates.

However, further studies are needed to test the effectiveness of these molecules by in vivo tests. 

The data that support the findings of this study are available from the corresponding authors upon reasonable request. 

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Antiviral treatment of covid-19

Natural and synthetic drugs as potential treatment for coronavirus disease 2019 (COVID-2019)

Potential treatment of COVID-19

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Treatment options for COVID-19: the reality and challenges

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection

Novel chalcone derivatives containing a 1,2,4-triazine moiety: design, synthesis, antibacterial and antiviral activities

Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos

Bioactive natural products with anti-herpes simplex virus properties

Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease

Synthesis, antioxidant and DNA cleavage activities of novel indole derivatives

Design of potent fluorosubstituted chalcones as antimicrobial agents

Synthesis, biological evaluation, and molecular modeling of chalcone derivatives as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatases (PtpA and PtpB)

A comprehensive review of chalcone derivatives as antileishmanial agents

A review of anti-infective and anti-inflammatory chalcones

Comparativestudies of inhibitory activities of chalcones on tomato ringspot virus (ToRSV)

Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV

Synthesis of xanthoxyline derivatives with antinociceptive and antioedematogenic activities

Antiviral activity of the volatile oils of Melissa officinalis L. against Herpes simplex virus type-2

Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Viral load quantitation of SARS-coronavirus RNA using a one-step realtime RT-PCR

To interpret the SARS-CoV-2 test, consider the cycle threshold value

Practical comparison of the biofire filmarray pneumonia panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections

An efficient synthesis of novel di-heterocyclic benzazole derivatives and evaluation of their antiproliferative activities

New molecule design with in-silico methods for Covid-19 treatment

Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents

Bisbenzoxazole derivatives: design, synthesis, in vitro antimicrobial, antiproliferative activity, and molecular docking studies

Synthesis and characterization of some novel fluoro and methoxy substituted chalcone derivatives via nucleophilic aromatic substitution

Gopal, duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2

Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNAdependent RNA polymerase (RdRp)

In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19

Molecular docking and dynamic simulations of some medicinal plants compounds against SARS-CoV-2: an in-silico study

Head-to-head bisbenzazole derivatives as antiproliferative agents: design, synthesis, in-vitro activity, and SAR analysis

A new coronavirus associated with human respiratory disease in China

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

New chalcone derivatives as effective against SARS-CoV-2 agent

TA B L E 4 Some predicted toxicological, ADME, and drug-like properties